<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03910751</url>
  </required_header>
  <id_info>
    <org_study_id>POLESTAR_EMC2019</org_study_id>
    <nct_id>NCT03910751</nct_id>
  </id_info>
  <brief_title>POLESTAR Trial - An International Multi-center Early Discharge TAVI Program</brief_title>
  <acronym>POLESTAR</acronym>
  <official_title>Project to Look for Early Discharge in Patients Undergoing TAVI With ACURATE - An International Multi-center Early Discharge TAVI Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An international multi-center prospective observational study to address safety and&#xD;
      feasibility of an early discharge protocol in patients with symptomatic severe aortic&#xD;
      stenosis who are eligible for transfemoral TAVI with the Boston Scientific ACURATE Neo Aortic&#xD;
      Bioprosthesis transcatheter heart valve.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this International multi-center prospective observational study, 250 patients with severe&#xD;
      symptomatic aortic stenosis (AS) and eligibility for transfemoral TAVI with ACURATE Neo&#xD;
      Bioprosthesis, will be pre-procedurally selected for participation in an early discharge&#xD;
      protocol in which patients are discharged within 48 hours after uncomplicated TAVI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Primary safety endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>Composite of all-cause mortality, any stoke, life threatening bleeding, acute kidney injury, coronary artery obstruction, major vascular complication and valve-related dysfunction requiring repeat procedure at 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary efficacy endpoint at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Composite of all-cause mortality, all stroke, all-cause re-hospitalization at 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary efficacy endpoint at 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>Composite of all-cause mortality, all stroke, all-cause re-hospitalization at 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life threatening bleeding</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary artery obstruction requiring intervention</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major vascular complication</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve related dysfunction requiring repeat procedure</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause rehospitalization</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization for valve-related symptoms or worsening congestive heart failure</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New permanent pacemaker implantation</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA heart failure class III or IV</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As defined by the most recent VARC document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported Quality of Life</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As measured by the EQ5D-5L quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported Quality of Life</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>As measured by the KCCQ quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical cost analysis</measure>
    <time_frame>30 days</time_frame>
    <description>Derived from length of stay on Intensive care unit and general ward</description>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Aortic Valve Implantation with ACURATE Neo Aortic Bioprosthesis</intervention_name>
    <description>Transfemoral TAVI using the Boston Scientific ACURATE Neo Aortic Bioprosthesis</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        250 patients with severe AS and selected for TF-TAVI with the ACURATE Neo valve and&#xD;
        eligible for early discharge within 48 hours post TAVI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible for ACURATE Neo valve implantation&#xD;
&#xD;
          -  Patient agrees to follow-up duration&#xD;
&#xD;
          -  Patient is able to understand and sign written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &gt; 35&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
        Cardiac&#xD;
&#xD;
          -  Moderate to severely impaired left ventricular ejection fraction (LVEF &lt;35%)&#xD;
&#xD;
          -  Mitral regurgitation &gt; moderate&#xD;
&#xD;
          -  Pulmonary hypertension (sPAP &gt; 60mmHg)&#xD;
&#xD;
          -  No complex coronary artery disease&#xD;
&#xD;
          -  Untreated high degree AV-block or RBBB&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  COPD Gold &gt; 2&#xD;
&#xD;
        Kidney function&#xD;
&#xD;
          -  GFR &lt; 35ml/min&#xD;
&#xD;
        Frailty&#xD;
&#xD;
          -  Inappropriate social support and/or (familial) care&#xD;
&#xD;
          -  Patient is walking aid dependent&#xD;
&#xD;
        TAVI strategy&#xD;
&#xD;
          -  Presence of severe peripheral artery disease&#xD;
&#xD;
          -  Transfemoral approach not possible&#xD;
&#xD;
        Follow up&#xD;
&#xD;
          -  Inability to adhere to follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Van Mieghem, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ASZ Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utrecht University Medical Center</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Nicolas van Mieghem</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>TAVR</keyword>
  <keyword>Early discharge</keyword>
  <keyword>ACURATE Neo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

